sur Takeda Pharmaceutical Company Limited (isin : JP3463000004)
Julie Kim to Take Over as CEO of Takeda in 2026
Takeda Pharmaceutical Company Limited has announced that Julie Kim will succeed Christophe Weber as CEO in June 2026. Weber will retire after a 12-year tenure. Kim, currently the President of Takeda's U.S. Business Unit, will be proposed for election to the Board at the company's 2026 Annual General Shareholders Meeting.
The decision was unanimous among the Board of Directors, who praised Kim's leadership in the U.S. market and the Plasma-Derived Therapies Business Unit. Masami Iijima, Chair of the Board, noted that Kim’s selection comes after a comprehensive succession process.
Chrisophe Weber cited the company’s positive growth outlook and upcoming product launches as a fitting time for leadership transition. He expressed confidence in Kim’s capabilities, noting her dedication and impact within the company.
Kim, honored by the appointment, aims to continue Takeda's mission and values, contributing to patient care and business success globally.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Takeda Pharmaceutical Company Limited